A Method for Approximating Future Entry of Generic Drugs

Value in Health

Volumn 21, Issue 12, 2018, Pages 1382-1389

  Beall, Reed F ^a   Darrow, Jonathan J ^a   Kesselheim, Aaron S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

drug costs; drug legislation; drug regulation; FDA; generic drugs; pharmaceutical patents

Indexed keywords

GENERIC DRUG; DRUG;

ACCURACY; ARTICLE; DATA BASE; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; MEDICAID; PATENT; PRIORITY JOURNAL; CHEMISTRY; DRUG CONTROL; DRUG INDUSTRY; ECONOMIC ASPECT; ECONOMICS; FACTUAL DATABASE; HUMAN; REGISTER; REPRODUCIBILITY; THEORETICAL MODEL; UNITED STATES; VALIDATION STUDY;

DATABASES, FACTUAL; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; HUMANS; MEDICAID; MODELS, THEORETICAL; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; REGISTRIES; REPRODUCIBILITY OF RESULTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85048287119     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2018.04.1827     Document Type: Article

References (42)

1. Grabowski, H.G., Long, G., Mortimer, R., Boyo, A., Updated trends in US brand-name and generic drug competition. J Med Econ 19 (2016), 836–844.
2. Grabowski, H.G., Vernon, J.M., Effective patent life in pharmaceuticals. Int J Technol Manag 19 (2000), 98–120.
3. Hemphill, C.S., Sampat, B.N., Evergreening, patent challenges, and effective market life in pharmaceuticals. J Health Econ 31 (2012), 327–339.
4. Wang, B., Liu, J., Kesselheim, A.S., Variations in time of market exclusivity among top-selling prescription drugs in the United States. JAMA Intern Med 175 (2015), 635–637.
5. US Food and Drug Administration. Generic competition and drug prices. Available from: https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129385.htm. [Accessed March 1, 2018].
6. Kesselheim, A.S., Avorn, J., Sarpatwari, A., The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 316 (2016), 858–871.
7. Dave, C.V., Kesselheim, A.S., Fox, E.R., et al. High generic drug prices and market competition: a retrospective cohort study. Ann Intern Med 167 (2017), 145–151.
8. US Government Accountability Office. Drug industry: profits, research, and development spending, and merger and acquisition deals. Available from: https://www.gao.gov/assets/690/688472.pdf. [Accessed March 1, 2018].
9. Ho, P.M., Bryson, C.L., Rumsfeld, J.S., Medication adherence: its importance in cardiovascular outcomes. Circulation 119 (2009), 3028–3035.
10. Ho, P., Rumsfeld, J.S., Masoudi, F.A., et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 166 (2006), 1836–1841.
11. Gagne, J.J., Choudhry, N.K., Kesselheim, A.S., et al. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med 161 (2014), 400–407.
12. Fung, V., Reed, M., Price, M., et al. Responses to Medicare drug costs among near-poor versus subsidized beneficiaries. Health Serv Res 48 (2013), 1653–1668.
13. Vokinger, K., Kesselheim, A.S., Avorn, J., Sarpatwari, A., Strategies that delay market entry of generic drugs. JAMA Intern Med 177 (2017), 1665–1669.
14. Kesselheim, A.S., Sinha, M.S., Avorn, J., Determinants of market exclusivity for prescription drugs in the United States. JAMA Intern Med 177 (2017), 1658–1664.
15. Kapczynski, A., Park, C., Sampat, B.N., Polymorphs and prodrugs and salts (oh my!): an empirical analysis of “secondary” pharmaceutical patents. PLoS One, 7, 2012, e49470.
16. Hemphill, C.S., Sampat, B.N., When do generics challenge drug patents? J Empir. Leg Stud 8 (2011), 613–649.
17. Higgins, M.J., Graham, S.J.H., Balancing innovation and access: patent challenges tip the scales. Science 326 (2009), 370–371.
18. Grabowski, H.G., Kyle, M., Generic competition and market exclusivity periods in pharmaceuticals. Manage Decis Econ 28 (2007), 491–502.
19. US Patent and Trademark Office. Patent terms extended under 35 USC §156. Available from: https://www.uspto.gov/patent/laws-and-regulations/patent-term-extension/patent-terms-extended-under-35-usc-156. [Accessed March 1, 2018].
20. US Government Publishing Office. Extension of patent term—35 USC §156. Available from: https://www.gpo.gov/fdsys/granule/USCODE-2011-title35/USCODE-2011-title35-partII-chap14-sec156. [Accessed March 1, 2018].
21. Hemphill, C.S., Sampat, B.N., Archival Orange Book Data [Data file]. 2013, Columbia University, Mailman School of Public Health; Department of Health Policy and Management, New York, New York.
22. US Food and Drug Administration. Orange Book: approved drug products with therapeutic equivalence evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/. [Accessed March 1, 2018].
23. US Patent and Trademark Office. USPTO's Patent Full-Text and Image Database. Available from: http://patft.uspto.gov/netahtml/PTO/search-adv.htm. [Accessed March 1, 2018].
24. The Drug Price Competition and Patent Term Restoration Act of 1984, Public Law 98-417, 98 Stat. 1585 (codified at 21 U.S.C. 355(b), (j), (l); 35 U.S.C. 156, 271, 282) (Hatch-Waxman Act).
25. Beall, R.F., Kesselheim, A.S., Tertiary patenting on drug–device combination products in the United States. Nat Biotechnol 36 (2018), 142–144.
26. National Institutes of Health Best Pharmaceuticals for Children Act. Best Pharmaceuticals for Children Act (BPCA). Available from: https://bpca.nichd.nih.gov/Pages/default.aspx. [Accessed March 1, 2018].
27. US Food and Drug Administration. Food and Drug Administration Modernization Act (FDAMA) of 1997. Available from: https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDAMA/ucm089179.htm. [Accessed March 1, 2018].
28. US Food and Drug Administration. Patents and exclusivity. Available from: https://www.fda.gov/downloads/drugs/developmentapprovalprocess/smallbusinessassistance/ucm447307.pdf. [Accessed March 1, 2018].
29. US Food and Drug Administration. CFR - Code of Federal Regulations Title 21. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.108. [Accessed March 1, 2018].
30. US Food and Drug Administration. CFR - Code of Federal Regulations Title 21. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=316&showFR=1&subpartNode=21:5.0.1.1.6.4. [Accessed March 1, 2018].
31. US Food and Drug Administration. Drugs@FDA: FDA approved drug products. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/. [Accessed March 1, 2018].
32. US Food and Drug Administration. Pediatric exclusivity granted. 2017. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm050005.htm. [Accessed March 1, 2018].
33. Philippidis A. The top 15 best-selling drugs of 2016. Available from: https://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868. [Accessed March 1, 2018].
34. Beall, R.F., Nickerson, J.W., Kaplan, W.A., Attaran, A., Is patent “evergreening” restricting access to medicine/device combination products?. PLoS One, 11, 2016, e0148939.
35. Luo, J., Kesselheim, A.S., Evolution of insulin patents and market exclusivities in the USA. Lancet Diabetes Endocrinol 3 (2015), 835–837.
36. US Food and Drug Administration. Paragraph IV patent certifications. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm047676.htm#p1. [Accessed March 1, 2018].
37. American Intellectual Property Law Association. 2015 report of the economic survey. Available from: http://www.aipla.org/learningcenter/library/books/econsurvey/2015EconomicSurvey/Pages/default.aspx. [Accessed March 1, 2018].
38. US Patent and Trademark Office. Inter partes review. Available from: https://www.uspto.gov/patents-application-process/appealing-patent-decisions/trials/inter-partes-review. [Accessed March 1, 2018].
39. Darrow, J.J., Beall, R.F., Kesselheim, A.S., Will inter partes review speed US generic drug entry?. Nat Biotechnol 35 (2017), 1139–1141.
40. Wallach, E.J., Darrow, J.J., Federal Circuit review of USPTO inter partes review decisions, by the numbers. J Pat Trademark Off Soc, 98, 2016, 105.
41. Orangebookblog. Citizen petition, states of Kansas, Minnesota, Vermont, and Wisconsin. Docket No. FDA-2006-P-0282. 2006. Available from: http://www.orangebookblog.com/files/governors_citizen_petition.pdf. [Accessed March 1, 2018].
42. Kesselheim, A.S., Darrow, J.J., Hatch-Waxman turns thirty: Do we need a redesigned approach for the modern era?. Yale J Health Policy Law Ethics 15 (2015), 293–347.